Trial Profile
A Randomized, Controlled Study to Evaluate the Sensitizing Potential of PEP005 Topical Gel (0.01% Concentration) in Healthy Volunteers Using a Repeat Insult Patch Test Design
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Jun 2009
Price :
$35
*
At a glance
- Drugs Ingenol mebutate (Primary)
- Indications Actinic keratosis; Skin cancer
- Focus Adverse reactions
- Sponsors Peplin
- 04 Jun 2009 New trial record.